15
Participants
Start Date
April 30, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
Fenretinide
Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
Placebo
A matching placebo will be used to keep the study double-blind.
Montreal Chest Institute, Montreal
Elias Matouk
OTHER